TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assistive Hip Exoskeleton Study for Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-85 years~* Had stroke over 6 months prior~* Greater than 17 on minimental state examination (MMSE)~* Sit unsupported for a minimum of 30 seconds~* Follow a 3 step command.~* Ability to walk without support (a rail as needed is allowed), with a walking speed of at least 0.4 m/s (limited community ambulatory speed)~* Ability to walk for at least 6 minutes~* Willingness and ability to participate over a 1-4 hour experiment, with breaks enforced regularly and as needed~* Ability to transfer (sit-to-stand and stand-to-sit) with no external support (arm rests support allowed)~* Ability to ambulate over small slopes (3 degrees) and a few steps (6 steps)~Exclusion Criteria:~* Loss of sensation in the legs~* A complete spinal cord injury~* History of concussion in the last 6 months~* History of any severe cardiovascular conditions~* Severe arthritis~* Orthopedic problems that limit lower extremity passive range of motion (knee flexion contracture of \>10 degrees, knee flexion active ROM 15 degrees)~* Pre-existing neurological and other disorders such as Parkinson's disease, ALS, MS, dementia~* History of head trauma~* Lower extremity amputation~* Non-healing ulcers of a lower extremity~* Renal dialysis or end state liver disease~* Legal blindness or severe visual impairment~* Uses a pacemaker~* Has a metal implants in the head region~* Uses medications that lower seizure thresholds.~* Lastly, if the subject is participating in another clinical trial and/or subject's condition relating to criteria that, in the opinion of the Principal Investigator (PI), would likely affect the study outcome or confound the results, subject will be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Individuals post-stroke using a powered hip exoskeleton (Type: EXPERIMENTAL): This study will be conducted on a sample population of stroke subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women the age of majority in their country~* Has pathologically documented breast cancer that:~  1. is unresectable or metastatic~ 2. has HER2 positive expression confirmed per protocol~* Has an adequate tumor sample~* Has at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1~* Has protocol-defined adequate cardiac, renal and hepatic function~* Agrees to follow protocol-defined method(s) of contraception~Exclusion Criteria:~* Has a medical history of myocardial infarction, symptomatic congestive heart failure (CHF) (NYHA classes II-IV), unstable angina or serious cardiac arrhythmia~* Has a corrected QT interval (QTc) prolongation to \> 450 millisecond (ms) in males and \> 470 ms in females~* Has a medical history of clinically significant lung disease~* Is suspected to have certain other protocol-defined diseases based on imaging at screening period~* Has history of any disease, metastatic condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:~  1. safety or well-being of the participant or offspring~ 2. safety of study staff~ 3. analysis of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-8201a Low Dose (Type: EXPERIMENTAL): T-DM1 resistant/refractory (R/R) patients in the low dose treatment group
- DS-8201a Medium Dose (Type: EXPERIMENTAL): T-DM1 resistant/refractory (R/R) patients in the medium dose treatment group
- DS-8201a High Dose (Type: EXPERIMENTAL): T-DM1 resistant/refractory (R/R) patients in the high dose treatment group
- Exploratory Arm (Type: OTHER): In Part 2b- Continuation Stage, about 10 T-DM1 Intolerant patients will receive the DS-8201a recommended dose (RD) as an exploratory arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults with a diagnosis of Attention Deficit/Hyperactivity Disorder (ADHD) according to DSM-IV criteria~* ADHD symptoms from childhood to adulthood, with some symptoms present before age 7 years which continue to meet DSM-IV criteria at the time of assessment. (ADHD is not diagnosed if the symptoms are better accounted for by another psychiatric disorder.)~Exclusion Criteria:~* Patients known to be a non-responder to methylphenidate or known to have a child who is a non-responder to methylphenidate~* treated with any methylphenidate-containing medication within 1 month of starting the study~* have any clinically unstable psychiatric condition including, but not limited to the following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder, anti-social personality disorder, borderline personality disorder~* family history of schizophrenia or affective psychosis~* patients with motor tics or a history of Tourette's syndrome, or with a substance abuse or dependence disorder, an eating disorder, or mental retardation~* using any medications which may affect the evaluation of study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to provide written informed consent (either from patient or patient's legally acceptable representative)~2. Male or female patients 21 years of age or older with BMI ≥ 20 to ≤ 40 kg/m2~3. Patients with alcoholic hepatitis defined as:~   1. History of heavy alcohol abuse: \> 40 g/day in females or \> 60 g/day in males for a minimum period of 6 months, AND~  2. Consumed alcohol within 12 weeks of entry into the study, AND~  3. Serum bilirubin \> 3 mg/dL AND AST \> ALT, but less than 300 U/L AND~  4. MELD score between 11-30, inclusive~4. No evidence of active infection as determined by the investigator.~5. Women of child-bearing potential must utilize appropriate birth control throughout the study duration.~6. Male patients must agree to use a medically acceptable method of contraception/birth control throughout the study duration~Exclusion Criteria:~1. Other or concomitant cause(s) of liver disease as a result of:~   1. Autoimmune liver disease~  2. Wilson disease~  3. Vascular liver disease~  4. Drug induced liver disease~2. Co-infection with human immunodeficiency virus (HIV) or Hepatitis B~3. Any active malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas)~4. If female, known pregnancy, or has a positive serum pregnancy test, or lactating/breastfeeding~5. Serum creatinine \> 2.5 mg/dL~6. Patients who have had organ transplantation (such as liver, kidney, lung, heart, bone marrow, or stem cell etc.), other than cornea transplant~7. Stage 3 or greater encephalopathy by West Haven criteria

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A (Moderate AH) DUR-928 30 mg (Type: EXPERIMENTAL): Lowest dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
- Part A (Moderate AH) DUR-928 90 mg (Type: EXPERIMENTAL): Middle dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
- Part A (Moderate AH) DUR-928 150 mg (Type: EXPERIMENTAL): Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
- Part B (Severe AH) DUR-928 30 mg (Type: EXPERIMENTAL): Lowest dose of dose escalation arms: 30mg, 90 mg and 150 mg
- Part B (Severe AH) DUR-928 90 mg (Type: EXPERIMENTAL): Middle dose of dose escalation arms: 30mg, 90 mg and 150 mg
- Part B (Severe AH) DUR-928 150 mg (Type: EXPERIMENTAL): Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Building Community Capacity for Disability Prevention for Minority Elders (Positive Minds - Strong Bodies)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60+~* Fluency in English, Spanish, Mandarin or Cantonese~* Score above threshold on PHQ-9, GAD-7, or Geriatric Depression Scale (GDS-Short Form)~* Score within threshold of SPPB~Exclusion Criteria:~* Participants will be excluded if there is evidence of:~* Current substance use disorders~* Current or last 3 months of specialty mental health treatment~* Evidence that patient the participant lacks capacity to consent assessed using the UCSD Brief Assessment of Capacity to Consent.~* Suicidal risk (score of 4 or 5 on the Paykel suicide questionnaire), whereby participant will be referred for immediate treatment to specialty care~* If the participant's physician advises against strenuous physical exercise.~* Exclusion from the disability component will also happen if the participant is home-bound, has an acute or an exacerbated chronic disease, or has neuro-musculoskeletal impairment that prevents them from participating in the exercises

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CBT + InVEST exercise (Type: EXPERIMENTAL): 10 sessions of individual CBT plus 36 sessions of InVEST group exercise, provided over a 12-week intervention period.
- Enhanced Usual Care (Type: ACTIVE_COMPARATOR): Usual care, as accessed through the community-based organization, plus written material from the NIH on depression, anxiety, and physical health for elders.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have one of the following diagnoses and/or treatment plans:~  * Newly diagnosed de novo AML~ * First or subsequent relapse of AML~ * Secondary AML~ * Treatment with institutional standard AML therapy in those without AML (for example, myelodysplastic syndrome, bone marrow blasts \> 5% or biphenotypia)~ * Note: Patients with a history of prolonged antifungal therapy (example, relapsed AML) are eligible~* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 OR a serum creatinine based on age/gender as follows:~  * =\< 0.4 mg/dL (age 1 month to \< 6 months)~ * =\< 0.5 mg/dL (age 6 months to \< 1 year)~ * =\< 0.6 mg/dL (age 1 to \< 2 years)~ * =\< 0.8 mg/dL (age 2 to \< 6 years)~ * =\< 1 mg/dL (age 6 to \< 10 years)~ * =\< 1.2 mg/dL (age 10 to \< 13 years)~ * =\< 1.4 mg/dL (females age \>= 13 years)~ * =\< 1.5 mg/dL (males age 13 to \< 16 years)~ * =\< 1.7 mg/dL (males age \>= 16 years)~* Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age AND Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) \< 2.5 x ULN for age~* All patients and/or their parents or legal guardians must sign a written informed consent~Exclusion Criteria:~* Patients with the following diagnoses are not eligible:~  * Acute promyelocytic leukemia (APL)~ * Down syndrome~ * Juvenile myelomonocytic leukemia (JMML)~* Patients with a documented history of invasive fungal infection (IFI) within the previous 30 days are not eligible~* Patients with a history of echinocandin or fluconazole hypersensitivity are not eligible~* Patients receiving treatment for an IFI are not eligible~* Female patients of childbearing age must have a negative pregnancy test~* Patients must agree to use an effective birth control method~* Lactating patients must agree not to nurse a child while on this trial

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (caspofungin acetate) (Type: EXPERIMENTAL): Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC \> 100-500/uL following the nadir or the next chemotherapy course begins.
- Arm II (fluconazole) (Type: ACTIVE_COMPARATOR): Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject has provided informed consent~* Male or female, ≥ 18 to ≤ 85 years~* History of chronic heart failure (HF), defined as requiring treatment for HF for a minimum of 30 days before randomization~* Left ventricle ejection fraction (LVEF) ≤ 35%, per subjects most recent medical record, within 12 months prior to screening.~* New York Heart Association (NYHA) class II to IV at most recent screening assessment.~* Managed with HF standard of care (SoC) therapies consistent with regional clinical practice guidelines according to investigator judgment of subject's clinical status~* Current hospitalization with primary reason of HF OR one of the following events within 1 year of screening: hospitalization with primary reason of HF; urgent visit to emergency department (ED) with primary reason of HF.~* Elevated B-type natriuretic peptide (BNP) or n-terminal-prohormone brain natriuretic peptide (NT-proBNP)~Other Inclusion Criteria May apply~Key Exclusion Criteria:~* Currently receiving treatment in another investigational device or drug study, or \< 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.~* Malignancy within 5 years prior to randomization with the following exceptions: localized basal or squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, stage 1 prostate carcinoma, breast ductal carcinoma in situ.~* Subject has known sensitivity to any of the products or components to be administered during testing~Other Exclusion Criteria May apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Omecamtiv Mecarbil (Type: EXPERIMENTAL): Participants received oral omecamtiv mecarbil (OM) twice daily in addition to standard heart failure therapy. The starting dose of OM was 25 mg; At week 4, participants with week 2 OM predose plasma concentrations \< 200 ng/mL had their dose increased to 50 mg BID; participants with week 2 predose plasma concentrations ≥ 200 and \< 300 ng/mL had their dose increased to 37.5 mg BID and participants with week 2 predose plasma concentrations ≥ 300 ng/mL and \< 1000 ng/mL maintained a 25 mg BID dosing regimen.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo tablets twice a day in addition to standard heart failure therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bone Properties in Hypoparathyroidism: Effects of PTH

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hypoparathyroidism~Exclusion Criteria:~* Bisphosphonate use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTH(1-84) (Type: EXPERIMENTAL): 100mcg of PTH1-84 every other day, every day, or every three days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TAASS-Traumeel Ointment and Gel Compared With a Topical NSAID in Athletes With Acute Ankle Sprain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Athletes with an acute unilateral ankle sprain of the lateral ligaments of the ankle joint both male and female~* Moderate (30-60 mm) to severe (\>60 mm) pain according to the patient's assessment of ankle pain visual analogue scale (VAS) on weight bearing, unable to perform normal training / sports activities~* 18 - 40 years of age~* injury occurred within 24 hours of the first dose of study medication~* Willing and able to give written informed consent~* Available for the duration of the study~Exclusion Criteria:~* Similar injury affecting the same joint within the past 6 months~* bilateral ankle injury~* bed rest, hospitalization, surgery use of a non-removable rigid cast~* Clinically important abnormality for screening laboratory tests~* Debilitating acute or chronic illness~* Use of corticosteroids in the previous 8 weeks, any analgesics in the previous 6 hours, or 24 hours in case of long-acting NSAID, COX-2 specific inhibitors, or tramadol~* History of sensitivity to any component of the study drugs~* Unwilling or unable to comply with all the requirements of the protocol~* Participation in other studies within 4 weeks prior to study entry and or during the study participation~* Current substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of the study result

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Traumeel S ointment (Type: EXPERIMENTAL): Traumeel S ointment 2 g, 3 times daily topical during 14 days
- Traumeel S gel (Type: EXPERIMENTAL): Traumeel S gel 2 g, 3 times daily topical during 14 days
- Diclofenac gel (Type: ACTIVE_COMPARATOR): Diclofenac gel 2 g, 3 times daily topical during 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Nosocomial Infection by Decontamination of the Naso- and Oropharynx With Chlorhexidine (NONI Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all adult patients (above 18) who were scheduled to undergo sternotomy for cardiothoracic surgery~Exclusion Criteria:~* emergency procedures, a preoperative infection and/or the use of antibiotics, hypersensitivity to chlorhexidine gluconate (CHX), absence of written informed consent or presence of an alternative prophylactic regimen like selective decontamination of the digestive tract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete